Company Quick10K Filing
Amedisys
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 33 $3,941
10-Q 2019-10-30 Quarter: 2019-09-30
10-Q 2019-08-01 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-28 Annual: 2018-12-31
10-Q 2018-10-30 Quarter: 2018-09-30
10-Q 2018-08-01 Quarter: 2018-06-30
10-Q 2018-05-08 Quarter: 2018-03-31
10-K 2018-02-28 Annual: 2017-12-31
10-Q 2017-11-08 Quarter: 2017-09-30
10-Q 2017-07-27 Quarter: 2017-06-30
10-Q 2017-05-03 Quarter: 2017-03-31
10-K 2017-03-01 Annual: 2016-12-31
10-Q 2016-11-04 Quarter: 2016-09-30
10-Q 2016-08-03 Quarter: 2016-06-30
10-Q 2016-05-04 Quarter: 2016-03-31
10-K 2016-03-10 Annual: 2015-12-31
10-Q 2015-11-05 Quarter: 2015-09-30
10-Q 2015-07-29 Quarter: 2015-06-30
10-Q 2015-04-29 Quarter: 2015-03-31
10-K 2015-03-04 Annual: 2014-12-31
10-Q 2014-10-29 Quarter: 2014-09-30
10-Q 2014-07-30 Quarter: 2014-06-30
10-Q 2014-05-08 Quarter: 2014-03-31
10-K 2014-03-12 Annual: 2013-12-31
10-Q 2013-11-12 Quarter: 2013-09-30
10-Q 2013-07-31 Quarter: 2013-06-30
10-Q 2013-04-30 Quarter: 2013-03-31
10-Q 2012-11-06 Quarter: 2012-09-30
10-Q 2012-08-07 Quarter: 2012-06-30
10-Q 2012-05-09 Quarter: 2012-03-31
10-K 2012-02-28 Annual: 2011-12-31
10-Q 2011-11-01 Quarter: 2011-09-30
10-Q 2011-08-02 Quarter: 2011-06-30
10-Q 2011-04-26 Quarter: 2011-03-31
10-K 2011-02-22 Annual: 2010-12-31
10-Q 2010-10-26 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-04-27 Quarter: 2010-03-31
10-K 2010-02-23 Annual: 2009-12-31
8-K 2020-01-14 Regulation FD, Exhibits
8-K 2020-01-02 Regulation FD, Exhibits
8-K 2019-11-25 Regulation FD, Exhibits
8-K 2019-10-29 Earnings, Regulation FD, Earnings, Exhibits
8-K 2019-10-17
8-K 2019-07-31 Earnings, Regulation FD, Earnings, Exhibits
8-K 2019-07-25 Regulation FD, Exhibits
8-K 2019-06-07 Shareholder Vote
8-K 2019-04-30 Earnings, Regulation FD, Earnings, Exhibits
8-K 2019-04-01 Regulation FD, Exhibits
8-K 2019-02-27 Earnings, Regulation FD, Earnings, Exhibits
8-K 2019-02-25 Regulation FD, Exhibits
8-K 2019-02-19 Regulation FD, Exhibits
8-K 2019-02-12 Enter Agreement, Officers, Regulation FD, Exhibits
8-K 2019-02-01 Enter Agreement, M&A, Off-BS Arrangement, Regulation FD, Exhibits
8-K 2019-01-08 Regulation FD, Exhibits
8-K 2018-10-29 Earnings, Regulation FD, Earnings, Exhibits
8-K 2018-10-09 Enter Agreement, Regulation FD, Exhibits
8-K 2018-10-03 Regulation FD, Exhibits
8-K 2018-09-27 Officers, Exhibits
8-K 2018-08-29 Regulation FD, Exhibits
8-K 2018-07-31 Regulation FD, Exhibits
8-K 2018-07-31 Earnings, Regulation FD, Earnings, Exhibits
8-K 2018-06-29 Enter Agreement, Off-BS Arrangement, Regulation FD, Exhibits
8-K 2018-06-06 Officers, Shareholder Vote, Exhibits
8-K 2018-06-04 Enter Agreement, M&A, Regulation FD, Exhibits
8-K 2018-05-18 Enter Agreement
8-K 2018-05-07 Earnings, Regulation FD, Earnings, Exhibits
8-K 2018-04-20 Officers, Regulation FD, Exhibits
8-K 2018-02-27 Earnings, Officers, Regulation FD, Earnings, Exhibits
8-K 2018-01-10 Regulation FD, Exhibits

Amedisys Financials

AMED Metrics, Comps, Filings

Annual | Quarterly

Business

Amedisys, Inc. is a leading healthcare services company focused on providing care in the home. Our operations involve serving patients across the United States through our three operating divisions: home health, hospice and personal care. We deliver clinically distinct care that best suits our patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury, care that empowers patients to manage a chronic disease, hospice care at the end of life, or providing assistance with daily activities through our personal care division.

We are among the largest, pure play providers of home health and hospice care in the United States, with 472 care centers in 38 states within the United States and the District of Columbia. Our 21,000 employees deliver the highest quality care making more than ten million visits to more than 376,000 patients annually. Over 3,000 hospitals and 65,000 physicians nationwide have chosen us as a partner in post-acute care.

Due to the age demographics of our patient base, our services are primarily paid for by Medicare which has represented approximately 73% to 79% of our net service revenue over the last three years. We also remain focused on maintaining a profitable and strategically important managed care contract portfolio.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
CVS (CVS) 71,271 32% 11.6 2% 218,904 157,305 226,770 72,447 4,334 11,702 135,768
Walgreens Boots (WBA) 49,162 22% 6.9 7% 68,586 43,814 136,354 30,423 4,828 8,710 60,251
Chemed (CHE) 5,769 31% 20.5 18% 1,094 476 1,837 573 201 286 5,851
Teladoc (TDOC) 4,519 67% -68.7 -7% 1,565 563 493 332 -108 -59 4,078
Autolus Therapeutics (AUTL) 3,969 0% -161.3 -8% 254 22 0 0 -21 -23 3,752
Spark Therapeutics (ONCE) 3,953 37% -16.7 -31% 750 349 58 21 -231 -229 3,827
Amedisys (AMED) 3,941 22.8 10% 1,206 643 0 0 125 185 4,205
Repligen (RGEN) 3,939 56% 65.1 2% 1,068 189 233 129 27 57 3,721
US Physical Therapy (USPH) 1,538 23% 20.4 10% 557 193 473 109 54 77 1,570
Addus HomeCare (ADUS) 1,001 27% 26.9 5% 409 119 566 153 19 37 984
Civitas Solutions (CIVI) 636 20% 8.1 1% 1,100 927 1,613 327 12 158 1,277
Concord Medical Services Holdings (CCM) 476 0% 4,585 2,312 0 0 0 0 191
Diplomat Pharmacy (DPLO) 448 6% -2.7 -36% 1,315 1,016 5,278 339 -472 -337 901
Rite Aid (RAD) 371 21% 18.6 -6% 10,530 9,494 21,624 4,634 -603 203 3,785
PetMed Express (PETS) 321 32% 6.0 21% 145 21 276 87 31 40 237
BioScrip (BIOS) 301 34% -19.3 -8% 601 676 735 250 -49 -42 808
LHC Group (LHCG) 4 37% -0.2 5% 2,030 566 2,037 744 104 154 -23
AdaptHealth (AHCO)
111 (YI)

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash34120481517828308620
Accounts Receivable15014214816911199125166201189
Inventory
PP&E9213914915715913743373129
Assets1,1721,300858731726670685734813717
Accounts Payable17232529201626302529
Long-Term Debt1711451121033310495938911
Liabilities436420338276354272275273297234
Stockholders' Equity735878519452372397410460515482
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue
Cost of Revenue724820782841718691726833901993
Gross Profit
R&D
SG&A482501
Tax8672-103-21-59-2-1215039
Net Income136113-382-99-9813-23831120
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating24820614269102-6610862106223
Cash Investing-97-74-181-60-46-14-67-52-44-22
Cash Financing-119-47-33-43-5371-21-8-6-267